Cohort lymphoma t cell. Medical search. Frequent questions

A population-based cohort study in Taiwan showed that HBV infection was significantly associated with an increased risk of diffuse large B-cell lymphoma (DLBCL) but not with the risk of T-cell NHL and follicular lymphoma (FL). (medscape.com)
Purpose: Patients with diffuse large B-cell lymphoma (DLBCL) are typically treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). (htlv.net)
Recent reports have divided diffuse large B cell lymphoma (DLBCL) into germinal centre B cell-like and activated B cell-like subgroups with implicated differences in prognosis. (bmj.com)
Diffuse large B cell lymphoma (DLBCL) is a clinically and morphologically heterogeneous group of lymphomas. (bmj.com)
3 Hence, the new World Health Organisation classification has grouped "diffuse proliferation of large neoplastic B lymphoid cells with nuclear size equal to or exceeding normal macrophage nuclei" under the umbrella term of DLBCL. (bmj.com)
Aggressive B-cell lymphoma: includes DLBCL and subtypes, transformed lymphoma, Burkitt lymphoma, as well as high-grade B-cell lymphoma with MYC and/or BCL2 and/or BCL6 rearrangement(s). (nih.gov)
Non-GCB DLBCL: includes DLBCL NOS and subtypes, transformed lymphoma, THRLBCL, as well as high-grade B-cell lymphoma with MYC and/or BCL6 rearrangement(s). (nih.gov)
The most common subtype of NHLs that arise primarily from the thyroid gland is diffuse large-cell lymphoma (DLBCL). (medscape.com)
Diffuse large B-cell lymphoma (DLBCL), T-cell/histiocyte-rich large B-cell lymphoma, Epstein-Barr virus-positive DLBCL of the elderly, Grade 3b Follicular Lymphoma, highgrade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements (double-hit or triple-hit lymphoma), histological transformation from an earlier diagnosis of low-grade lymphoma (such as FL, MZL, CLL) into DLBCL. (everyone.org)
The core group includes patients with DLBCL (NOS and transformed from follicular lymphoma) that are ECOG Performance Status 0-1. (businesswire.com)
Announced the Regenerative Medicine Advanced Therapy (RMAT) designation for investigational drug JCAR017 for the treatment of r/r aggressive large B cell NHL , including DLBCL, not otherwise specified (de novo or transformed from indolent lymphoma), primary mediastinal B Cell lymphoma or Grade 3B follicular lymphoma. (businesswire.com)
PATIENTS AND METHODS: Paraffin-embedded lymphoma samples from 193 patients with de novo DLBCL who were uniformly treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) were studied using immunohistochemistry for MYC, BCL2, CD10, BCL6, and MUM1/interferon regulatory factor 4, and fluorescent in situ hybridization (FISH) for MYC and BCL2. (duke.edu)
Home Topics Cancer Epizyme Halts Phase II Trial of Tazemetostat in DLBCL Cohorts, Continues Talks. (genengnews.com)
Epizyme said today it will halt a Phase II clinical trial assessing its lead candidate, the cancer treatment tazemetostat in cohorts of patients with relapsed and/or refractory diffuse large B-cell lymphoma (r/r DLBCL), but continue the study in follicular lymphoma (FL) cohorts. (genengnews.com)
The company said it will end its Phase II trial evaluating tazemetostat as monotherapy in cohorts of patients with r/r DLBCL ( NCT01897571 ). (genengnews.com)
as well as cohorts of DLBCL patients with EZH2 activating mutations, and with wild-type EZH2 who have been receiving tazemetostat as monotherapy. (genengnews.com)
Epizyme has conducted an interim assessment of data from this trial and concluded that the clinical activity seen in these cohorts is not sufficient to warrant further development of tazemetostat in DLBCL as a monotherapy or in combination with prednisolone," the company said in a statement, tucked within its announcement of second-quarter results. (genengnews.com)
The terminated trial was designed to assess tazemetostat in non-Hodgkin lymphoma (NHL), of which DLBCL is the most common form. (genengnews.com)
Although a lymph node biopsy could not be obtained, a bone marrow biopsy revealed the activated B‑cell subtype of diffuse large B‑cell lymphoma (DLBCL). (spandidos-publications.com)
Yescarta was the first CAR T-cell therapy to be approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, and high grade B-cell lymphoma and DLBCL arising from follicular lymphoma. (gilead.com)
Xencor has dosed the first patient in a potentially registration-enabling Phase 2 study, evaluating plamotamab in combination with tafasitamab plus lenalidomide, in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). (biospace.com)
Expansion cohorts in the Phase 1 study of plamotamab are actively recruiting patients with DLBCL and follicular lymphoma (FL) and are dosing using the recommended Phase 2 regimen to further evaluate the safety and efficacy of plamotamab as a monotherapy. (biospace.com)

POLIVY is a CD79b-directed antibody-drug conjugate indicated in combination with bendamustine and a rituximab product for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified, after at least two prior therapies. (nih.gov)
Adults ages 18 and older with relapsed and/or refractory B-cell lymphoma who have had at least one prior cancer treatment. (nih.gov)
The bispecific T-cell engager blinatumomab was the first such agent to be approved by the U.S. Food and Drug Administration (FDA) in patients with relapsed or refractory B-cell acute lymphocytic leukemia (ALL). (ascopost.com)
Phase I study of tirabrutinib (ONO-4059/GS-4059) in patients with relapsed or refractory B-cell malignancies in Japan. (cdc.gov)
The Food and Drug Administration (FDA) has granted accelerated approval to Lunsumio ® (mosunetuzumab-axgb) for the treatment of adults with relapsed or refractory (R/R) follicular lymphoma (FL) after 2 or more lines of systemic therapy. (empr.com)
This approval is a significant milestone for people with relapsed or refractory follicular lymphoma, who have had limited treatment options until now," said Elizabeth Budde, MD, PhD, Haematologic Oncologist and Associate Professor, City of Hope Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, and Lunsumio clinical trial investigator. (empr.com)
FDA approves Roche's Lunsumio, a first-in-class bispecific antibody, to treat people with relapsed or refractory follicular lymphoma. (empr.com)
The purpose of this trial is to study whether the condition of patients with relapsed or refractory non Hodgkin lymphoma (NHL) or chronic lymphocytic leukemia (CCL) improves on Tafasitamab plus Parsaclisib. (everyone.org)
Presentations at ASH will include data from the ongoing Phase I TRANSCEND study in patients with relapsed or refractory (r/r) aggressive B-cell NHL who were treated with fludarabine/cyclophosphamide lymphodepletion and JCAR017. (businesswire.com)
Aetna considers autologous hematopoietic cell transplantation for the treatment of persons with relapsed or primary refractory (see "Note" below) non-Hodgkin's lymphoma (NHL) medically necessary if the person meets the transplanting institution's protocol eligibility criteria. (aetna.com)
Aetna considers allogeneic hematopoietic cell transplantation medically necessary for the treatment of persons with relapsed NHL (including persons who have relapsed after autologous hematopoietic cell transplantation) or primary refractory (see "Note" below) NHL (low-grade, intermediate-grade, and high-grade) if the person meets the transplanting institution's protocol eligibility criteria. (aetna.com)
Aetna considers non-myeloablative allogeneic hematopoietic cell transplantation medically necessary ("mini-transplant", reduced intensity conditioning transplant) for the treatment of persons with relapsed NHL (including persons who have relapsed after ABMT) or primary refractory (see note below) NHL (low-grade, intermediate-grade, and high-grade) when they are eligible for conventional allografting or a reduced intensity regimen is preferred by the transplant center. (aetna.com)
This review will focus on innovative drug development for the treatment of relapsed or refractory MCL, including therapies aimed at disrupting the B-cell receptor signaling pathway, regulators of apoptosis, and immunomodulators. (cancernetwork.com)
SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite, a Gilead Company (Nasdaq: GILD), today announced four-year follow-up data from the pivotal ZUMA-1 trial of Yescarta ® (axicabtagene ciloleucel) in adult patients with refractory large B-cell lymphoma (LBCL). (gilead.com)
Of 111 patients enrolled in the ZUMA-1 Phase 2 cohorts, Yescarta was administered to 101 patients with refractory LBCL, and the median time from leukapheresis to complete response (CR) was less than two months. (gilead.com)
With close to half of patients still alive after a single infusion of axicabtagene ciloleucel, we are transforming the way relapsed or refractory large B-cell lymphoma can be treated," said Frederick L. Locke, MD, ZUMA-1 Co-Lead Investigator and Vice Chair of the Department of Blood and Marrow Transplant and Cellular Immunotherapy at Moffitt Cancer Center in Tampa, Florida. (gilead.com)
These results suggest that persistence of functional CAR T cells is not necessary for durable remissions in patients with refractory LBCL and may support long-term safety of the therapy. (gilead.com)
With these first-ever four-year data from a pivotal CAR T clinical trial in lymphoma, we continue to show the potential long-term survival of Yescarta in relapsed/refractory large B-cell lymphoma and push the boundaries of what is possible with this CAR T treatment," said Ken Takeshita, MD, Kite's Global Head of Clinical Development. (gilead.com)
Kite has presented four-year survival data for Yescarta in the ZUMA-1 study of patients with refractory large B-cell lymphoma. (gilead.com)

Aggressive non-Hodgkin lymphoma: Burkitt-like B cell lymphoma (n = 1), anaplastic T-cell lymphoma (n = 1), Diffuse large B cell lymphoma (n = 2). (cdc.gov)
7- 9 Diffuse lymphomas showing this trademark translocation between the bcl2 gene and the immunoglobulin heavy chain (IgH) locus are believed to have progressed from the more indolent follicular lymphoma. (bmj.com)
Targetable activating mutations are very frequent in GCB and ABC diffuse large B-cell lymphoma. (cdc.gov)
MYD88, CD79B, and CARD11 gene mutations in CD5-positive diffuse large B-cell lymphoma. (cdc.gov)
B-cell Function Gene Mutations in Diffuse Large B-cell Lymphoma: A Retrospective Cohort Study. (cdc.gov)
Mutations of the B-Cell Receptor Pathway Confer Chemoresistance in Primary Cutaneous Diffuse Large B-Cell Lymphoma Leg Type. (cdc.gov)
The diffuse large B-cell lymphoma cohort was deprioritized due to strategic and competitive reasons and did not enroll any patients. (itbusinessnet.com)
Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. (duke.edu)
PURPOSE: Approximately 5% of diffuse large B-cell lymphomas (DLBCLs) are double-hit lymphomas (DHLs) with translocations of both MYC and BCL2. (duke.edu)
Wang J, Huang J and Zeng Q: Network meta-analysis of targeted therapies for diffuse large B cell lymphoma. (spandidos-publications.com)

A similar pattern was observed for follicular-cell lymphoma, but no other lymphoma subtypes. (cdc.gov)

OBJECTIVES In response to a previous finding of increased mortality from lymphohaematopoietic (LH) malignancies, this study examines incidence of LH malignancy in a petrochemical industry cohort. (bmj.com)
Lower, non-significant increases were found for other lymphohaematopoietic (LH) malignancies, including non-Hodgkin's lymphoma (12 observed versus nine expected) and acute myelocytic leukaemia (eight observed versus five expected). (bmj.com)
Today, dozens of next-generation bispecific antibody constructs are in clinical trials, and they are poised to have a huge impact in the treatment of lymphoma and other hematologic malignancies, experts agreed. (ascopost.com)
This is the most exciting of the plenary abstracts and represents a fundamental change in how we conceptualize the treatment of B-cell malignancies. (ascopost.com)
primary thyroid lymphoma may constitute 1-8% of all thyroid malignancies and 1-7% of all extranodal lymphomas. (medscape.com)
11] Acting downstream of SYK, Bruton tyrosine kinase (BTK) is a promising target in a variety of B-cell malignancies, including MCL. (cancernetwork.com)
Standardized incidence ratios (SIR) for hospitalized infections and malignancies were compared with external RA cohorts and, for malignancies, with the US general population. (jrheum.org)

non-Hodgkin lymphoma (NHL) is the main subtype of lymphoma that originated from the lymphatic hematopoietic system. (medscape.com)
Ongoing research is warranted to discern if different environmental mechanisms may be driving B- and T-cell lymphoma immunophenotypes, consistent with previously reported regional differences in subtype prevalence. (biomedcentral.com)
Mantle cell lymphoma (MCL) is a distinct subtype of non-Hodgkin lymphoma that has been associated with a poor prognosis. (cancernetwork.com)
Introduction Enteropathy-associated T cell lymphoma (EATL) is usually a rare lymphoma subtype that is strongly associated with celiac disease (CD), an autoimmune disease triggered by the ingestion of gluten. (woofahs.com)
Enteropathy-associated T cell lymphoma (EATL) is certainly a uncommon lymphoma subtype that's strongly connected with Compact disc and posesses poor prognosis. (woofahs.com)
11, 12] The term Enteropathy Associated T cell lymphomas was first introduced by OFarrelly in 1986 [13], but it was only in 1991 when the World Health Business International Classification Project updated the terminology to Enteropathy type intestinal T-cell lymphoma that EATL formally became a recognized subtype. (woofahs.com)
Over the last year, oncologists have added new weapons to their arsenal against mantle cell lymphoma (MCL), an aggressive B-cell subtype of NHL that accounts for 6% of all cases of the disease. (cancertherapyadvisor.com)

A data update for the fully enrolled squamous non-small cell lung cancer cohort is expected in the fourth quarter of 2022. (itbusinessnet.com)
In 2022, we also expect to start Phase 1 studies for XmAb819, our ENPP3 x CD3 bispecific antibody for renal cell carcinoma engineered with our multivalent 2+1 format for greater tumor selectivity, and for XmAb808, our B7-H3 x CD28 bispecific antibody. (biospace.com)
Subcutaneous administration of plamotamab will be introduced this year, and the Company plans to present data from the expansion cohorts in the second half of 2022. (biospace.com)

The AHS cohort did not show a signifi cantly increased risk of non-Hodgkin lymphoma. (skepticalraptor.com)

In the first round of grants awarded in 2021, six institutions were awarded over $3 million to fund research focused on some of the deadliest childhood cancers, including neuroblastoma, pediatric acute lymphoma, and acute myeloid leukemia. (cancer.org)

15. IKZF1 alterations and expression of crlf2 predict prognosis in adult Chinese patients with B-cell precursor acute lymphoblastic leukemia. (nih.gov)
Aggressive ATL is associated with poor prognosis, as indicated by the 4-year overall survival rates of acute-type (11%) and lymphoma-type (16%) ATL 7 . (nature.com)
In brief, 270 patients with a poor prognosis were treated, many of whom had received CAR T-cell therapy previously. (ascopost.com)
The prognosis for patients with thyroid large-cell lymphoma usually is favorable because they typically present with localized disease, which is amenable to treatment with chemotherapy and radiation (see Treatment ). (medscape.com)

A retrospective cohort study of 191 children with a recent diagnosis of a haematolymphoid malignancy. (ecancer.org)
First off, it is important to point out that the goals of the retrospective multicenter general review of marginal zone lymphoma coordinated by Professor Steffen Heegaard in Denmark which also included some of our patients from M. D. Anderson was not to compare the efficacy of various treatment strategies. (bmj.com)
Nevertheless, despite the controversy, autologous SCT (ASCT) is frequently used based on the encouraging results from the Nordic Lymphoma Group prospective phase 2 clinical trial and data from multiple retrospective or registry studies 5-7 . (ebmt.org)
We explored the disease course of patients with small plaque or large plaque parapsoriasis in a 26-year retrospective cohort analysis of 105 parapsoriasis patients, who were clinically and histopathologically followed up in Helsinki and Tampere University Hospitals. (medicaljournals.se)

Projects in this second cohort of grantees focus on lymphoma chemotherapy treatment outcomes, immunotherapy development to treat leukemia and lymphoma, and gliomas, a deadly and difficult to treat pediatric cancer. (cancer.org)
Today we are pleased to announce we have dosed the first patient in a potentially registration-enabling study for plamotamab to evaluate the chemotherapy-free, triple combination with tafasitamab and lenalidomide for patients with an aggressive form of non-Hodgkin's lymphoma. (biospace.com)
There is no consensus on the role of consolidative stem cell transplantation (SCT) following frontline chemotherapy in patients with peripheral T cell lymphoma (PTCL), mainly due to the lack of large prospective randomized trials in that setting 1-4 . (ebmt.org)
Currently, MCL is treated using combination chemotherapy or chemotherapy plus immunotherapy , followed by stem cell transplantation. (cancertherapyadvisor.com)

Adult T cell leukemia-lymphoma (ATL) is an aggressive T cell malignancy caused by the human T cell leukemia virus type 1 (HTLV-1). (nature.com)
Non-small cell lung cancer (NSCLC) accounts for approximately 80-85% of lung cancer cases, which are the most common fatal malignancy and leading cause of cancer mortality worldwide ( 1 ). (frontiersin.org)
This surplus is certainly described by a rise in malignancy [8 mainly, 10], lymphomas notably, those taking place in the tiny bowel especially. (woofahs.com)

Versluis J , Pas SD , Agteresch HJ , de Man RA , Maaskant J , Schipper MEI , Hepatitis E virus: an underestimated opportunistic pathogen in recipients of allogeneic hematopoietic stem cell transplantation. (cdc.gov)
This Clinical Policy Bulletin addresses hematopoietic cell transplantation for non-hodgkin's lymphoma. (aetna.com)
Aetna considers tandem autologous hematopoietic cell transplantion (auto-auto) or tandem autologous hematopoietic cell transplantation followed by allogenic hematopoietic cell transplantation (auto-allo) experimental and investigational for NHL due to a lack of adequate evidence in the peer-reviewed published medical literature of their safety and effectiveness. (aetna.com)
Following intraperitoneal (i.p.) transplantation of 5x10 4 EL4 lymphoma cells rapid exponential proliferation with ascites volume and animal mass increase resulted in median survival of 14.5 days. (jcancer.org)
Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. (ebmt.org)

The Agricultur al Health Study (AHS) is a prospective cohort study including licensed private and commercial pesticide applicators in Iowa and North Carolina enrolled 1993-7. (cdc.gov)
The researchers scoured the medical literature for studies that looked at the effects of omega-3 fatty acids on tumor incidence, and they narrowed their search to studies with a prospective cohort design that considered different levels of omega-3 consumption. (natap.org)

Aggressive B-cell lymphomas can be cured but people with disease that resists treatment or that returns after treatment have poor outcomes with standard therapies. (nih.gov)
CAR T-cell therapies are here to stay, but the question is whether bispecific antibodies will encroach on them," he commented. (ascopost.com)
Among 193 patients evaluable for efficacy, 124 (65%) had aggressive lymphoma, and 67 (35%) had indolent lymphoma (but their cancer had failed to respond to other therapies). (ascopost.com)
Our broad clinical development programs and ongoing infrastructure and manufacturing investments remain a key part of our strategy to deliver on the potential of CAR T cell therapies for cancer patients across a broad array of diseases. (businesswire.com)
Similar to breakthrough designation, the pathway enables companies developing cell and tissue based therapies to have earlier and more frequent interactions with the FDA and includes opportunities for accelerated approval, priority review, rolling submissions, and alternative provisions to fulfill post-approval requirements under accelerated approval. (businesswire.com)
My research interests also include investigation of molecular and immune mechanisms underlying the poor clinical outcomes of lymphoma, the pathogenesis and evolution of drug resistant clones, and development of novel therapies for aggressive B-cell lymphoma. (duke.edu)
RNAi therapies are a unique approach to cancer treatment as they have the potential to 'turn off' the genes' coding for proteins involved in cancer cell division," said Dr. Ramesh K. Ramanathan, Medical Director of Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare and deputy director of the Clinical Translational Research Division of TGen. (tgen.org)

Mantle cell lymphoma (MCL) is an aggressive B-cell neoplasm that follows a heterogeneous clinical course. (nih.gov)
13. Gene copy number alteration profile and its clinical correlation in B-cell acute lymphoblastic leukemia. (nih.gov)
16. Immunoglobulin heavy chain locus chromosomal translocations in B-cell precursor acute lymphoblastic leukemia: rare clinical curios or potent genetic drivers? (nih.gov)
Furthermore, clonally expanded, premalignant cells harboring putative driver mutations were detected in the peripheral blood of individuals at high risk for ATL before clinical onset, indicating that the development of ATL involves the progressive accumulation of mutations within an infected T cell clone 12 . (nature.com)
Patients must have evaluable disease by clinical exam (i.e., palpable lymphadenopathy, measurable skin lesions, etc.), laboratory assessment (i.e., lymphoma involvement of bone marrow or peripheral blood by morphology, cytology or flow cytometry), and/or imaging (measurable lymph nodes or masses on CT or MRI and/or evaluable FDG-avid lesions on PET). (nih.gov)
Which Leukemia or Lymphoma patients can access this clinical trial? (everyone.org)
The clinical data continue to support our belief that a defined cell product can improve patient outcomes. (businesswire.com)
Epizyme added that it plans to present clinical data from each of the study cohorts at a medical meeting later this year. (genengnews.com)
In April, the FDA imposed its partial clinical hold on U.S.-based enrollment of new patients in clinical trials of tazemetostat after a patient in a Phase I pediatric study ( NCT02601937 ) developed a secondary T-cell lymphoblastic lymphoma (T-LBL). (genengnews.com)
In addition, Epizyme said, it has obtained new consent from all patients in its clinical trials and updated its informed consent form based on the safety report that followed the lymphoma case. (genengnews.com)
Internally we are focused on efficiently using our resources to advance the most promising clinical-stage programs, as well as the next wave of Xencor innovations to enter the clinic - more reduced-potency XmAb cytokines, CD28 T cell engagers and 2+1 CD3 T cell engagers," said Bassil Dahiyat, Ph.D., president and chief executive officer at Xencor. (biospace.com)

Anaplastic lymphoma kinase (ALK) protein may be detected in most cases (60-70%) of systemic ALCL by immunohistochemistry. (medscape.com)
Brigatinib is a central nervous system-active second-generation anaplastic lymphoma kinase (ALK) inhibitor that targets a broad range of ALK rearrangements in patients with non-small cell lung cancer (NSCLC). (frontiersin.org)
Anaplastic lymphoma kinase (ALK) gene rearrangement accounts for approximately 3-5% of advanced NSCLC ( 7 ). (frontiersin.org)

These circulating tumor cells (CTCs) and the DNA from these cancer cells (circulating tumor DNA [ctDNA]) can be detected with sensitive lab tests. (cancer.org)
An earlier suggestion of increased lung cancer risk at high levels of metolachlor use in this cohort was not confirmed in this update. (cdc.gov)
However, our findings for both liver cancer and follicular-cell lymphoma warrant follow-up to better differentiate effects of metolachlor use from other factors. (cdc.gov)
Lymphoma is the second most common cancer affecting Golden Retrievers and is hypothesized to arise through a complex interaction of genetic and environmental factors. (biomedcentral.com)
Forty-nine Golden Retrievers with non-cutaneous lymphoma and 98 Golden Retrievers without a history of cancer matched by age, sex and neuter status were selected from the Golden Retriever Lifetime Study cohort. (biomedcentral.com)
Lymphoma is a common cancer affecting dogs, particularly Golden Retrievers. (biomedcentral.com)
Prevalence and mortality of cancer among HIV/AIDS patients: a large-scale cohort study in Turkey. (who.int)
This study has a major advantage of more complete and reliable cancer ascertainment compared with the mortality investigation, and shows the feasibility and benefits of using cancer registry incidence data in an occupational cohort study. (bmj.com)
At a fundamental level, cancer is caused by an accumulation of genetic changes that result in unregulated cell growth and proliferation. (medscape.com)
A rare complication associated with textured surfaced implants is a type of lymphoma (cancer of the immune system) known as breast implant-associated anaplastic large-cell lymphoma (BIA-ALCL). (wikipedia.org)
Basem M. William, MD, MRCP (UK), FACP , Director of the T-Cell Lymphoma Program and Member of the Blood and Marrow Transplant Program at The Ohio State University Comprehensive Cancer Center, Columbus, agreed. (ascopost.com)
A cohort study of 2215 patients with primary thyroid lymphoma from the Surveillance, Epidemiology, and End Results (SEER) database of the National Cancer Institute reported 5- and 10-year overall survival rates of 71.61% and 55.95%, respectively. (medscape.com)
T-cell-engaging bispecific (TCB) EGFRxCD3 program - CX-904 is a conditionally activated TCB designed to target the epidermal growth factor receptor (EGFR) on cancer cells and the CD3 receptor on T cells within the tumor microenvironment, and is partnered with Amgen. (itbusinessnet.com)
Patient enrollment into the Phase 2 expansion study is now complete in all three solid cancer indications, including the esophageal/gastro-esophageal junction (E/GEJ) cancer cohort. (itbusinessnet.com)
Data from the E/GEJ cancer cohort continues to mature. (itbusinessnet.com)
Using a lipid nanoparticle, the RNAi drug can be delivered to a cancer cell to block the expression of specific proteins involved in tumor growth. (tgen.org)
Our preclinical results have shown that by decreasing PLK1 levels in cancer cells, we can stop tumor growth and kill the cancer cells," Dr. Ramanathan said. (tgen.org)
XmAb306 is a potency-reduced IL15/IL15Rα-Fc fusion protein targeting NK and T cells for the treatment of patients with cancer. (biospace.com)
Transcriptomic profiling of T-cell populations in non-muscle invasive and muscle invasive bladder cancer. (lu.se)
VSV-GP128 is a recombinant live-attenuated Vesicular Stomatitis Virus (VSV), modified to minimize the potential of neurotoxicity for humans and skin disease in animals, and engineered to contain cancer antigens, which help it induce an immune response against colorectal tumour cells. (biosafety.be)
The reviewers identified 20 cohorts from seven countries for 11 different types of cancer, and up to six different ways to categorize omega-3 fatty acid consumption. (natap.org)
A large body of literature spanning numerous cohorts from many countries and with different demographic characteristics does not provide evidence to suggest a significant association between omega-3 fatty acids and cancer incidence," Dr. MacLean and colleagues wrote. (natap.org)

1. Multi-Cohort Transcriptomic Subtyping of B-Cell Acute Lymphoblastic Leukemia. (nih.gov)
11. crlf2 -Positive B-Cell Acute Lymphoblastic Leukemia in Adult Patients: A Single-Institution Experience. (nih.gov)
14. Genome-Wide Single-Nucleotide Polymorphism Array Analysis Improves Prognostication of Acute Lymphoblastic Leukemia/ lymphoma . (nih.gov)

In this study, we sequenced 77 samples from a population-based de novo MCL cohort to investigate the utility of targeted sequencing in guiding personalized treatment approaches. (nih.gov)
Italian Cooperative Group for the Study of Hairy Cell Leukemia (ICGHCL). (nih.gov)
12. Splenectomy after initial therapy with alpha-IFN in patients with hairy-cell leukemia (HCL): a multi-center study by the Italian Cooperative Group for HCL. (nih.gov)
Data from 6 patients of this cohort were previously reported in a preliminary study ( 6 ). (cdc.gov)
METHODS: In the Opposites Attract observational cohort study, serodiscordant male homosexual couples were recruited from 13 clinics in Australia, one in Brazil, and one in Thailand. (cdc.gov)
The aim of this nested case-control study was to investigate the association between potential environmental pollutant sources and lymphoma risk among Golden Retrievers participating in the Golden Retriever Lifetime Study. (biomedcentral.com)
Using a subset of dogs from the Golden Retriever Lifetime Study, we sought to investigate whether dogs with lymphoma were more likely to live near certain environmental pollutant sources than dogs without lymphoma. (biomedcentral.com)
METHOD The study cohort consists of 8942 employees who were active in the period 1970-92 and alive on 31 December 1982. (bmj.com)
Denker S, Bittner A, Na IK, Kase J, Frick M, Anagnostopoulos I, Hummel M and Schmitt CA: A phase I/II first-line study of R-CHOP plus B-cell receptor/NF-κB-double-targeting to molecularly assess therapy response. (spandidos-publications.com)
The study was performed on ascitic EL4 lymphoma in an exponential growth phase focusing on the rapidly changing tumor susceptibility to the Dox treatment. (jcancer.org)
This concept will be investigated in this study by closely examining the metabolic profile of immune cells to see how the transplant affects their metabolism. (msaustralia.org.au)
He and his colleagues have been enrolling patients with advanced solid tumors or lymphoma into the ongoing multicenter, open-label, dose-escalation study. (tgen.org)
The study consists of two parts, a safety run-in intended to establish the safety of the triple combination (Part 1) and a two-arm, open-label cohort where patients will be randomized to receive either the triple combination or tafasitamab plus lenalidomide (Part 2). (biospace.com)
In an ongoing Phase 1 dose-escalation study of XmAb306 in patients with advanced solid tumors, XmAb306 has promoted high levels of sustained NK cell expansion and evidence of peripheral effector T cell proliferation. (biospace.com)
In this study, we demonstrated the underlying mechanism of why radiotherapy failed to induce sufficient T cell infiltration and proposed an effective strategy to promote T cell infiltration and sensitize radiotherapy. (bvsalud.org)
The overall age and sex-adjusted annual incidence for all those bowel lymphomas was 0.016 per 100,000, which increased over the study period from 0.006 to 0.024 per 100,000. (woofahs.com)

Mantle Cell Lymphoma (MCL) with documentation of either overexpression of cyclin D1 or t(11;14). (everyone.org)

95% CI: 1.11-2.12), but not with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) and Burkitt lymphoma. (medscape.com)

Here we develop and utilize a capture-based sequencing panel, which covers host hotspot genes and the full-length genome of human T-cell leukemia virus type-1 (HTLV-1), to investigate the clonal architecture of adult T-cell leukemia-lymphoma (ATL). (nature.com)

Previous studies have focused on the relationship between hepatitis B virus (HBV) infection and non-Hodgkin lymphoma (NHL). (medscape.com)
The association between benzene exposure and non-Hodgkin lymphoma (NHL) has been the subject of debate as a result of inconsistent epidemiologic evidence. (nih.gov)
Mosunetuzumab is an off-the-shelf product, requiring no time for manufacturing, and appears to work well even in patients with advanced non-Hodgkin lymphoma (NHL) whose disease progresses after treatment with chimeric antigen receptor (CAR) T-cell therapy. (ascopost.com)
Primary thyroid Hodgkin lymphoma is extremely rare. (medscape.com)
In two European studies, in which large cohorts of non-Hodgkin lymphoma (NHL) patients were screened serologically for R428 supplier CD and compared with controls, CD was found to be associated with an overall increased risk for developing NHL with a standardized incidence proportion (SIR) of 2.2 (95% confidence interval (CI) 1.2C3.6)[15] and 3.1 (95% CI, 1.3- 7.6). (woofahs.com)
Case-control studies of occupational exposure in the USA, Canada, and Sweden reported increased risks for non-Hodgkin lymphoma that persisted after adjustment for other pesticides. (skepticalraptor.com)

1. Recombinant interferon-alpha-2b treatment of hairy-cell leukaemia: experience with a low-dose schedule. (nih.gov)
17. Treatment of hairy-cell leukaemia with alpha-interferon (alpha-IFN). (nih.gov)

PC-ALCL is one of the primary cutaneous CD30 + T-cell lymphoproliferative disorders, a wide spectrum of disease, with lymphomatoid papulosis (LyP) at the benign end of the spectrum and PC-ALCL at the malignant end. (medscape.com)
Multistep mutations in the T-cell receptor (TCR), STAT3, and NOTCH pathways establish clone-specific transcriptomic abnormalities and further accelerate their proliferative potential to develop highly malignant clones, leading to disease onset and progression. (nature.com)
Mosunetuzumab binds to CD20 on the surface of malignant B cells and to CD3 on the surface of cytotoxic T cells, resulting in crosslinking of the T-cell receptor and subsequent activation of an immunologic T-cell response. (ascopost.com)
The broad cyclin-dependent kinase (CDK) inhibitor flavopiridol leads to downregulation of cyclin D1 and induces apoptosis of malignant lymphocytes in vitro and in murine lymphoma models. (cancernetwork.com)
The viral E7 protein expressed in pre-malignant cells has been identified as an ideal target for immunological intervention. (bvsalud.org)
Inhibiting BTK with ibrutinib causes cell death and decreases cellular migration and adhesion in malignant B-cells. (cancertherapyadvisor.com)

However, it also exhibits a significant capacity to infect and replicate in peripheral blood mononuclear cells, including lymphocytes. (medscape.com)

We have found that higher CD8+ T cell infiltration is associated with longer overall survival of lung adenocarcinoma and melanoma patients receiving radiotherapy. (bvsalud.org)

pRB functions as a negative regulatory transcription factor during the G1 to S phase cell cycle transition. (medscape.com)
p53 is a transcription factor whose expression is increased by DNA damage and blocks cell division at the G1 phase of the cell cycle to allow DNA repair. (medscape.com)

MCL is characterized by overexpression of cyclin D1, a cell cycle regulator that promotes cellular proliferation. (cancernetwork.com)

Multiple mutations were detected within the signaling pathways involving T cell function and differentiation. (nature.com)
Having dual specificity, they can redirect T cells to tumor cells to enhance tumor killing, simultaneously block two different signaling pathways or mediators with unique or overlapping functions, interact with two different surface antigens, and deliver payloads to targeted sites. (ascopost.com)
The domestic dog ( Canis lupus familiaris ) is considered to be an excellent animal model for human disease, with over 350 diseases in common-from hip dysplasia to lymphoma-and similar pathways and genes often underlie these shared diseases 1 . (nature.com)
Secondary genetic events that enhance cell growth, activate cell survival pathways, inhibit apoptosis, and promote interactions with the tumor microenvironment also serve as potential targetable mechanisms of lymphomagenesis. (cancernetwork.com)
Conclusion: The successful expression of HPV16 E7 in cells demonstrates that the replicated recombinant virus retains the replication and infection abilities of Ad4, while also upregulating the CD36 gene involved in the PI3K-Akt signaling and p53 pathways, thereby promoting cell proliferation. (bvsalud.org)

Tumor suppressor genes encode proteins that normally provide negative control of cell proliferation. (medscape.com)
Proto-oncogenes are genes that function normally in healthy cells to promote growth and proliferation. (medscape.com)

Researchers have found that in many breast cancers, cells may break away from the tumor and enter the blood. (cancer.org)

ALCL was recognized in 1985, when tumor cells consistently demonstrated labeling by the monoclonal antibody Ki-1, a marker later shown to recognize the CD30 antigen. (medscape.com)
This might also be an easy way to collect tumor cells to test for new drugs or sensitivities to currently available drugs before actually giving them. (cancer.org)
8-Gray radiation increased the transcriptional levels of chemokines in tumor cells in vitro. (bvsalud.org)

They included newly diagnosed patients with ALK negative systemic anaplastic large cell lymphoma (sALCL) or non-sALCL CD30+ PTCL. (ebmt.org)

The most common Grade 3 or 4 laboratory abnormalities (incidence at least 10%) were decreased lymphocyte count, decreased phosphate, increased glucose, decreased neutrophil count, increased uric acid, decreased white blood cell count, decreased hemoglobin, and decreased platelets. (empr.com)
however, incidence rates were comparable with RA cohorts. (jrheum.org)
In addition, the incidence of safety events in longterm biologic-treated patients should be evaluated against the incidence in comparator cohorts of DMARD-treated patients and the overall population, to determine whether increased risks are associated with biologic treatment. (jrheum.org)

PTEN encodes a protein kinase of the same name and functions as a tumor suppressor through regulation of cell proliferation. (medscape.com)
The hypothesis is that chronic antigenic stimulation secondary to the autoimmune disorder leads to chronic proliferation of lymphoid tissue, which eventually undergoes a mutation that leads to the development of lymphoma. (medscape.com)
Spleen tyrosine kinase (SYK) is amplified in some patients with MCL, and its inhibition leads to the arrest of cell proliferation and apoptosis. (cancernetwork.com)

The 5- and 10-year lymphoma-specific survival rates were 85.7% and 82.2%, respectively. (medscape.com)
As a practicing oncologist I continue to see these patients in the clinic, and this overall survival data confirms the durability of CAR T-cell therapy in a patient population that previously exhausted all viable treatment options. (gilead.com)
However, agents such as ibrutinib and lenalidomide have recently demonstrated an ability to improve progression-free survival (PFS) and overall survival (OS) by targeting B-cell receptor signaling. (cancertherapyadvisor.com)

11-13] More specifically, evidence that MCL pathogenesis is antigen-dependent[14] and that these tumors exhibit constitutive B-cell receptor (BCR) activation[15] posits the BCR signaling pathway as a rational prospect for drug development. (cancernetwork.com)

MCL is excluded given increased risk of tumor lysis syndrome (TLS) with venetoclax compared to other non-Hodgkin lymphomas and need for venetoclax ramp-up, dose-escalation. (nih.gov)

2. Long-term results of alpha interferon as initial therapy and splenectomy as consolidation therapy in patients with hairy cell leukemia. (nih.gov)
3. Treatment of hairy cell leukemia with granulocyte colony-stimulating factor and recombinant consensus interferon or recombinant interferon-alpha-2b. (nih.gov)
4. Relapse after interferon alfa-2b therapy for hairy-cell leukemia: analysis of prognostic variables. (nih.gov)
5. Low-dose interferon alfa-2b in the treatment of hairy cell leukemia. (nih.gov)
6. The alpha 2 (r) interferon in the treatment of hairy cell leukemia: progressive report of 25 cases. (nih.gov)
7. Prolonged, continuous treatment of hairy cell leukemia patients with recombinant interferon-alpha 2a. (nih.gov)
8. Five years follow-up after 2-chloro deoxyadenosine treatment in thirty patients with hairy cell leukemia: evaluation of minimal residual disease and CD4+ lymphocytopenia after treatment. (nih.gov)
9. [Effectiveness of gamma interferon and alpha interferon in hairy cell leukemia]. (nih.gov)
10. [Results of treatment in patients with hairy cell leukemia with splenectomy, alpha-interferon and deoxycoformycin]. (nih.gov)
11. Splenectomy following complete response to alpha interferon (IFN) therapy in patients with hairy cell leukemia (HCL): results of the HCL88 protocol. (nih.gov)
13. Durability of responses to interferon alfa-2b in advanced hairy cell leukemia. (nih.gov)
14. Hairy cell leukemia. (nih.gov)
15. Sequential evaluation of alpha-2b-interferon treatment in 128 patients with hairy cell leukemia. (nih.gov)
16. [The dose of alpha interferon in induction and maintainance therapy of hairy cell leukemia]. (nih.gov)
18. Very low dose alpha-2b interferon for the treatment of hairy cell leukemia. (nih.gov)
Acute myeloid leukemia (AML) is characterized by an increasing number of clonal myeloid blast cells which are incapable of differentiating into mature leukocytes. (mdpi.com)
In my research program, we focus on molecular mechanisms of tumor progression, cell-of-origin, biomarkers, and novel therapeutic strategies in lymphoma, myeloma and leukemia. (duke.edu)

To delineate the germinal centre B cell derivation group from an Asian series of DLBCLs. (bmj.com)
The t(14;18) chromosomal translocation is reported to occur in more than 80% of follicular lymphomas, and 7-38% of DLBCLs. (bmj.com)

My research efforts have been focused on identifying prognostic and therapeutic biomarkers in B-cell lymphoma. (duke.edu)

Anatomy29

Organisms14

Diseases39

Chemicals and Drugs87

Analytical, Diagnostic and Therapeutic Techniques and Equipment47

Phenomena and Processes42

Disciplines and Occupations1

Information Science6

Health Care17

DLBCL22

Refractory19

Diffuse10

Subtypes1

Malignancies7

Subtype7

20223

Risk of Non-Hodgkin1

20211

Prognosis4

Retrospective4

Chemotherapy4

Malignancy3

Transplantation5

Prospective2

Therapies7

Clinical11

Anaplastic lympho3

Cancer22

Acute lymphobl3

Study16

Mantle1

Small lymphocy1

Adult T-cell l1

Hodgkin Lymphoma6

Leukaemia2

Malignant6

Peripheral1

Lung1

Phase2

Overexpression of cyclin1

Pathways5

Genes2

Cancers1

Tumor cells3

Systemic1

Incidence3

Proliferation3

Survival3

Tumors1

Dose-escalation1

Leukemia17

DLBCLs2

Biomarkers1